Bristol-Myers Squibb Assets & Liabilities Overview 2006-2018 | BMY

Current and historical assets & liabilities overview for Bristol-Myers Squibb (BMY) from 2006 to 2018.
Bristol-Myers Squibb Annual Assets & Liabilities Overview
(Millions of US $)
Bristol-Myers Squibb Quarterly Assets & Liabilities Overview
(Millions of US $)
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $94.525B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $366.377B 17.18
Pfizer (PFE) United States $261.509B 15.31
Novartis AG (NVS) Switzerland $198.652B 17.04
Merck (MRK) United States $192.023B 16.96
AbbVie (ABBV) United States $139.177B 13.60
Eli Lilly (LLY) United States $119.245B 22.07
Sanofi (SNY) France $111.234B 14.08
Novo Nordisk (NVO) Denmark $106.025B 16.95
AstraZeneca (AZN) United Kingdom $98.986B 10.89
GlaxoSmithKline (GSK) United Kingdom $98.701B 13.18